RecruitingPhase 2NCT06830629

A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease

An Open-Label Phase 2 Study to Evaluate the Safety, Tolerability, and Effect on Albuminuria of MZE829 in Adults With Proteinuric Chronic Kidney Disease and the APOL1 High Risk Genotype

Sponsor

Maze Therapeutics

Enrollment

56 participants

Start Date

Feb 5, 2025

Study Type

INTERVENTIONAL

Conditions

Proteinuric Kidney Disease

Summary

This is purpose of this study is to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with APOL1 Kidney Disease

Eligibility

Min Age: 18 YearsMax Age: 68 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a new drug called MZE829 in adults who have kidney disease linked to a specific genetic variation called APOL1. Certain people — particularly those of African descent — carry gene variants (G1 or G2) that increase the risk of kidney disease. This Phase 2 trial is evaluating how safe and effective this new drug is for that group. **You may be eligible if...** - You carry two copies of the high-risk APOL1 gene variants (G1/G1, G2/G2, or G1/G2) - You have chronic kidney disease with significant protein in your urine (albuminuria) **You may NOT be eligible if...** - You have had an organ or bone marrow transplant - You have been diagnosed with cancer in the past 2 years (certain minor skin or early-stage cancers may be exceptions) - You have had bariatric (weight-loss) surgery or other conditions that affect how you absorb medications - You have Type 1 diabetes - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMZE829

Capsules for oral administration

Locations(81)

Research Site

Decatur, Alabama, United States

Research Site

Huntsville, Alabama, United States

Research Site

Montgomery, Alabama, United States

Research Site

Montgomery, Alabama, United States

Research Site

Granada Hills, California, United States

Research Site

Bloomfield, Connecticut, United States

Research Site

Atlantis, Florida, United States

Research Site

Brandon, Florida, United States

Research Site

Brooksville, Florida, United States

Research Site

Hollywood, Florida, United States

Research Site

Melbourne, Florida, United States

Research Site

Miami Lakes, Florida, United States

Research Site

Orlando, Florida, United States

Research Site

Atlanta, Georgia, United States

Research Site

College Park, Georgia, United States

Research Site

Cordele, Georgia, United States

Research Site

Lithia Springs, Georgia, United States

Research Site

Macon, Georgia, United States

Research Site

Riverdale, Georgia, United States

Research Site

Riverdale, Georgia, United States

Research Site

Savannah, Georgia, United States

Research Site

Snellville, Georgia, United States

Research Site

Chicago, Illinois, United States

Research Site

Chicago, Illinois, United States

Research Site

Kansas City, Kansas, United States

Research Site

Bowling Green, Kentucky, United States

Research Site

Louisville, Kentucky, United States

Research Site

Arnold, Maryland, United States

Research Site

Lutherville, Maryland, United States

Research Site

Oxon Hill, Maryland, United States

Research Site

Dearborn, Michigan, United States

Research Site

Flint, Michigan, United States

Research Site

Pontiac, Michigan, United States

Research Site

Saint Joseph, Michigan, United States

Research Site

Shelby, Michigan, United States

Research Site

Minneapolis, Minnesota, United States

Research Site

Tupelo, Mississippi, United States

Research Site

City of Saint Peters, Missouri, United States

Research Site

St Louis, Missouri, United States

Research Site

Las Vegas, Nevada, United States

Research Site

Buffalo, New York, United States

Research Site

Laurelton, New York, United States

Research Site

Maspeth, New York, United States

Research Site

New York, New York, United States

Research Site

Newburgh, New York, United States

Research Site

Durham, North Carolina, United States

Research Site

Fayetteville, North Carolina, United States

Research Site

Greensboro, North Carolina, United States

Research Site

Shelby, North Carolina, United States

Research Site

Cincinnati, Ohio, United States

Research Site

Cleveland, Ohio, United States

Research Site

Cleveland, Ohio, United States

Research Site

Columbus, Ohio, United States

Research Site

Ardmore, Oklahoma, United States

Research Site

Philadelphia, Pennsylvania, United States

Research Site

Philadelphia, Pennsylvania, United States

Research Site

Upland, Pennsylvania, United States

Research Site

Columbia, South Carolina, United States

Research Site

Spartanburg, South Carolina, United States

Research Site

Spartanburg, South Carolina, United States

Research Site

Chattanooga, Tennessee, United States

Research Site

Dallas, Texas, United States

Research Site

Dallas, Texas, United States

Research Site

Greenville, Texas, United States

Research Site

Houston, Texas, United States

Research Site

Houston, Texas, United States

Research Site

Houston, Texas, United States

Research Site

McKinney, Texas, United States

Research Site

San Antonio, Texas, United States

Research Site

Shenandoah, Texas, United States

Research Site

Sherman, Texas, United States

Research Site

Norfolk, Virginia, United States

Research Site

Créteil, France

Research Site

Lyon, France

Research Site

Paris, France

Research Site

Paris, France

Research Site

Saint-Ouen, France

Research Site

Leicester, United Kingdom

Research Site

London, United Kingdom

Research Site

London, United Kingdom

Research Site

London, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06830629

Related Trials

Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease

NCT05312879318 locations

Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without Comorbidities

NCT0679499635 locations